Nihon Bioresearch Inc.

Nihon Bioresearch Inc. is a Japanese contract research organization (CRO) headquartered in Hashima, Gifu Prefecture, where its main Hashima Laboratory is located. The company was established on February 16, 1982, and operates with a capital stock of 50 million yen. It is led by President Masumi Yoshida and employed 92 people as of October 2025. Its business is centered on non-clinical safety testing and animal studies conducted on behalf of pharmaceutical, medical device, regenerative medicine, and chemical companies. The company's service portfolio is organized around Good Laboratory Practice (GLP) compliance across several regulated categories. According to its corporate profile, it holds GLP compliance certificates for drugs, medical devices, regenerative medical products, and chemical substances, and it reports the results of its latest GLP inspections in each of these categories. This places Nihon Bioresearch among the specialized Japanese CROs that support the regulatory submission process for new therapies and products. Nihon Bioresearch operates a multi-site laboratory network. In addition to the Hashima Laboratory in Gifu, it maintains a Shuzenji Branch focused on minipigs and a Kisosansen Branch dedicated to infection studies. These facilities allow the company to offer species-specific and study-type-specific capabilities, from rodent toxicology to large-animal and infectious-disease research. The company also emphasizes animal welfare and quality accreditation. Its Shuzenji Branch and two divisions of the Hashima Laboratory have received certification from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), and its Hashima Laboratory and Kisosansen Branch hold certifications of animal studies from the Japan Pharmaceutical Information Center. Together, these credentials support its positioning as a trusted, compliance-oriented non-clinical research partner for the life sciences industry in Japan.

Nihon Bioresearch Inc. was established on February 16, 1982, in Japan. It built its operations around non-clinical safety testing and animal studies, a specialized segment of the life sciences service industry that supports pharmaceutical, medical device, regenerative medicine, and chemical companies in meeting regulatory requirements. The company is headquartered in Hashima, Gifu Prefecture, where its main Hashima Laboratory is based, and it operates with a capital stock of 50 million yen. Over time, the company expanded its laboratory footprint beyond the Hashima site. It established a Shuzenji Branch, which specializes in minipigs, and a Kisosansen Branch, which focuses on infection studies. This multi-site structure allows Nihon Bioresearch to match study types and animal species to dedicated facilities, covering rodent toxicology, large-animal research, and infectious-disease work. A central element of the company's development has been its pursuit of regulatory and quality accreditations. Nihon Bioresearch holds GLP compliance certificates for drugs, medical devices, regenerative medical products, and chemical substances. Its corporate profile reports the results of its latest GLP inspections in each category, with inspections for drugs, medical devices, and regenerative medical products complied as of September 11, 2024, and chemical substances complied as of September 30, 2024. The company has also sought external accreditation for its animal care and study quality. Its Shuzenji Branch received AAALAC International certification on November 23, 2020. Two divisions of the Hashima Laboratory subsequently received AAALAC certification: Division 1, covering buildings for mice, rats, and hamsters, on June 23, 2025, and Division 2, covering buildings for rabbits and guinea pigs, on February 23, 2026. In addition, the Hashima Laboratory and Kisosansen Branch received certifications of animal studies from the Japan Pharmaceutical Information Center, dated March 27, 2026, and March 14, 2026, respectively. As of October 2025, the company employed 92 people and was led by President Masumi Yoshida. It continues to position itself as a compliance-oriented non-clinical research partner for the Japanese life sciences industry.

• 2026

  Hashima Laboratory Division 2 (rabbits, guinea pigs) receives AAALAC International certification.

• 2026

  Kisosansen Branch receives certification of animal studies from the Japan Pharmaceutical Information Center.

• 2026

  Hashima Laboratory receives certification of animal studies from the Japan Pharmaceutical Information Center.

• 2025

  Hashima Laboratory Division 1 (mice, rats, hamsters) receives AAALAC International certification.

• 2025

  Company reports 92 employees as of October 2025.

• 2024

  GLP inspections for drugs, medical devices, and regenerative medical products are complied.

• 2024

  GLP inspection for chemical substances is complied.

• 2020

  Shuzenji Branch receives AAALAC International certification.

• 1982

  Nihon Bioresearch Inc. is established.

A GLP-compliant, AAALAC-accredited Japanese contract research organization specializing in non-clinical animal studies for drugs, medical devices, regenerative medical products, and chemical substances.

• GLP studies for drugs

  Non-clinical safety studies for pharmaceutical products under Good Laboratory Practice, with 13 inspections complied as of September 11, 2024.

• GLP studies for medical devices

  Non-clinical safety studies for medical devices under Good Laboratory Practice, with 7 inspections complied as of September 11, 2024.

• GLP studies for regenerative medical products

  Non-clinical safety studies for regenerative medical products under Good Laboratory Practice, with 4 inspections complied as of September 11, 2024.

• GLP studies for chemical substances

  Non-clinical safety studies for chemical substances under Good Laboratory Practice, with 12 inspections complied as of September 30, 2024.

• Minipig studies

  Studies conducted at the Shuzenji Branch, which is dedicated to minipigs.

• Infection studies

  Studies conducted at the Kisosansen Branch, which is dedicated to infection studies.

1. 1About Us | (株)日本バイオリサーチセンターnbr.co.jp
2. 2Nihon Bioresearch Inc. (Japan) - Wikidatawikidata.org